Plesner has assisted our long-time client Zealand Pharma with a record equity raise through an accelerated bookbuilding offering in a private placement raising proceeds of USD 1 billion / DKK 7 billion
Zealand Pharma is a Danish biotechnology listed on Nasdaq Copenhagen and is focused on the discovery and development of peptide-based medicines.
The proceeds enable Zealand to advance its proprietary obesity programs in Phase 2b clinical trials and beyond, including investment in associated CMC activities, and pursue clinical development in related indications with the potential to provide additional therapeutic benefits to patients and support continued early-stage research and fund general corporate purposes.
Plesner acted as legal advisor to Zealand Pharma in connection with the accelerated bookbuilding offering. Goldman Sachs International, Jefferies GmbH, Morgan Stanley and Nordea Danmark, Filial af Nordea Bank Abp, Finland acted as joint global coordinators and joint bookrunners and Van LanschotKempen N.V. acted as lead manager.
The transaction confirms Plesner's leading position within capital markets and as a preferred and experienced advisor within the biotech space.
Plesner's core team consisted of Thomas Holst Laursen, Micha Fritzen, Mikkel Rostock-Jensen, Sofie Riisgaard Mathiesen and Amalie Marie August Madsen.
Plesner's capital markets team is always looking for new colleagues.
Read more about our capital markets team and what it is like to work at Plesner